S10 Ep10: Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma
Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.
17m Jan 29, 2024
17m
S10 Ep9: FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL
Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated CLL/SLL; key efficacy and safety data from the BRUIN trial; and guidelines for pirtobrutinib use in clinical practice in the CLL/SLL patient population.
11m Jan 25, 2024
11m
S10 Ep8: Lunning and Maddocks Talk Through Frontline MCL Management
Dr Lunning sits down with Kami J. Maddocks, MD, of The Ohio State University Comprehensive Cancer Center––James, to discuss the management of MCL in the up-front setting, including practice-changing findings from the SHINE and TRIANGLE trials; how these trial data have altered the role of first-line BTK inhibitors in chemotherapy-free regimens for patients with MCL; and how patient characterist...
14m Jan 22, 2024
14m
S10 Ep7: FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.
7m Jan 15, 2024
7m
S10 Ep6: Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Drs Monk and Tarantino highlight current research investigating B7-H4–directed ADCs in multiple solid tumor types; other promising ADCs in development for gynecologic cancers; and future research needed to clarify unanswered questions regarding the sequencing of ADCs in breast cancer.
22m Jan 11, 2024
22m
S10 Ep5: Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management
Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new guidance regarding multidisciplinary management.
12m Jan 08, 2024
12m
S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.
14m Jan 04, 2024
14m
S10 Ep3: Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC
Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.
15m Jan 01, 2024
15m
S10 Ep2: Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL
Dr Jabbour discusses the activity and the utilization of olverembatinib in chronic myeloid leukemia and expanded upon the role that TKIs can play in the management of malignancies beyond chronic myeloid leukemia and acute lymphoblastic leukemia.
8m Dec 28, 2023
8m
S10 Ep1: Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
Dr Eskander discusses the impact of social determinants of health on cancer clinical trial participation; effective strategies for considering and engaging diverse communities in the clinical trial process; and how community partnerships can be strengthened to eliminate these financial and logistical barriers.
14m Dec 25, 2023
14m
S9 Ep50: Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
Dr Lunning and Neha Mehta-Shah, MD, MSCI, of Washington University School of Medicine, highlight challenges that arise when diagnosing patients with PTCL; how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma; and novel frontline agents under investigation in PTCL.
17m Dec 21, 2023
17m
S9 Ep49: Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.
25m Dec 18, 2023
25m
S9 Ep48: Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions
Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.
11m Dec 11, 2023
11m
S9 Ep47: Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer
Dr Abdou discusses how characteristics of patients with breast cancer impact ADC treatment selection and highlights some of the topline takeaways from breast cancer treatment to come out of the 2023 ASCO Annual Meeting.
15m Dec 07, 2023
15m
S9 Ep46: FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how the addition of toripalimab to the nasopharyngeal carcinoma treatment armamentarium increases the importance of multidisciplinary collaboration.
17m Dec 04, 2023
17m
S9 Ep45: Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Dr Lunning sits down with Caron A. Jacobson, MD, MMSc, or Dana-Farber Cancer Institute, to discuss the characteristics of FL that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.
15m Nov 30, 2023
15m
S9 Ep44: Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors
Dr Dumbrava discusses the rationale and design of the PYNNACLE trial; phase 1 efficacy and safety findings with PC14586 in patients with p53 Y220C–mutated advanced solid tumors; and the next steps for this research.
11m Nov 23, 2023
11m
S9 Ep43: FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.
8m Nov 20, 2023
8m
S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.
13m Nov 16, 2023
13m
S9 Ep41: Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes
Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on PFS outcomes for patients with pancreatic cancer.
12m Nov 13, 2023
12m
S9 Ep40: Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care beyond daratumumab, and the importance of confirming earlier post-hoc results from the placebo-controlled phase 3 VITAL trial in the ongoing AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.
13m Nov 09, 2023
13m
S9 Ep39: FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the CheckMate76K trial, and potential future directions for PD-1 inhibitor–based combinations in the melanoma treatment paradigm.
12m Nov 06, 2023
12m
S9 Ep38: Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma
Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may benefit most from standard chemotherapy vs clinical trial regimens in the frontline setting; and ongoing follicular lymphoma research that may alter the treatment paradigm.
15m Oct 30, 2023
15m
S9 Ep37: Naumann Discusses Notable Research Efforts in Endometrial Cancer
Dr Naumann discusses the role of frontline maintenance therapy for patients with endometrial cancer; which patients are likely to benefit from the RUBY and NRG-GY018 trial regimens; and ongoing research that may elucidate optimal treatments for patients with recurrent, dMMR disease.
7m Oct 26, 2023
7m
S9 Ep36: Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
Dr Keshava discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses.
10m Oct 23, 2023
10m
S9 Ep35: Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship
Dr Hasunuma shares that the objective of mentorship is to foster care, trust, and respect in mentor-mentee relationships and create authentic connections.
16m Oct 19, 2023
16m
S9 Ep34: FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia
Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.
12m Oct 16, 2023
12m
S9 Ep33: Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
Drs Gutierrez and Leslie discuss common barriers that institutions face when implementing CAR T-cell therapy programs, the early success story of outpatient administration of this modality at John Theurer Cancer Center, and future considerations for using this treatment approach in solid tumors.
15m Oct 12, 2023
15m
S9 Ep32: Expert Insights on the United States Chemotherapy Shortage
Oncology experts discuss the platinum chemotherapy shortage in the United States.
15m Oct 09, 2023
15m
S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS
Dr Platzbecker discusses the FDA approval of luspatercept in lower-risk MDS with anemia; key efficacy and safety data from the COMMANDS trial; and how this approval addresses historically unmet needs for patients with MDS.
11m Oct 05, 2023
11m
S9 Ep30: Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/refractory multiple myeloma, and the implications of this combination for heavily pretreated patients in this population.
25m Oct 02, 2023
25m
S9 Ep29: Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS
Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in MDS, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk MDS population.
30m Sep 28, 2023
30m
S9 Ep28: FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
19m Sep 21, 2023
19m
S9 Ep27: Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST
Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.
22m Sep 18, 2023
22m
S9 Ep26: Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer
Dr Chuong discusses the evolution of MRI-guided radiation in the cancer treatment armamentarium, the benefits of the MRIdian SMART system, and how Miami Cancer Institute is leading the way with trainings to expand the use of this technology.
16m Sep 14, 2023
16m
S9 Ep25: Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities
Dr Fonkoua discusses the ways in which common clinical trial enrollment criteria in oncology exclude patients from underrepresented groups, enrollment disparities that uniquely affect patients with liver cancer, and initiatives that Mayo Clinic is participating in to eliminate barriers to clinical trial enrollment.
16m Sep 11, 2023
16m
S9 Ep24: FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma
Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.
15m Sep 07, 2023
15m
S9 Ep23: Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.
15m Sep 04, 2023
15m
S9 Ep22: Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC
Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.
14m Aug 31, 2023
14m
S9 Ep21: FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer
Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.
12m Aug 28, 2023
12m
S9 Ep20: FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML
Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and safety data from the QuANTUM-First trial, and how this quizartinib regimen addresses an unmet need for older patients in this population.
11m Aug 21, 2023
11m
S9 Ep19: Trent Breaks Down Mutation Testing and ctDNA Monitoring in GIST
Dr Trent discusses the need for improved awareness around mutation testing in GIST, the limitations of current clinical trial criteria, and the potential for ctDNA to become a longitudinal cancer monitoring tool, helping to prevent invasive means of measuring disease progression.
8m Aug 17, 2023
8m
S9 Ep18: Bhatnagar Spotlights Ongoing Uproleselan Investigations in AML
Dr Bhatnagar discusses the prior and ongoing studies evaluating the addition of uproleselan to standard-of-care regimens for patients with AML, why uproleselan could affect the treatment paradigm across AML subtypes, and the rationale for pursuing minimal residual disease negativity as a clinical end point in AML.
14m Aug 14, 2023
14m
S9 Ep17: Sanai Spotlights Meningioma Symptoms, Treatment Options, and Research Needs
Dr Sanai discusses the prevalence and grading of malignant meningiomas; common symptoms associated with these tumors; treatment modalities for high-grade disease; and more.
20m Aug 10, 2023
20m
S9 Ep16: Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
Dr Danish discusses barriers to using radiotherapy for the treatment of patients with metastatic lung and bone cancers; the novel capabilities of SCINTIX biology-guided technology; and how John Theurer Cancer Center plans to use this technology and help advance its role in the field of radiation oncology.
15m Aug 07, 2023
15m
S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and the benefits of glofitamab’s mechanism of action.
21m Aug 03, 2023
21m
S9 Ep14: Trent Talks Through Potential Clinical Applications and Future Directions for MRD in GIST
Dr Trent discusses the current role and significance of using MRD in gastrointestinal stromal tumor, current guidelines around mutation testing, and research seeking to expand the targeted therapy armamentarium.
11m Jul 31, 2023
11m
S9 Ep13: Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL
Dr Lunning sits down with Manali Kamdar, MD, of the University of Colorado, to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.
21m Jul 24, 2023
21m
S9 Ep12: Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer
Drs Khan and Kwendakwema discuss the methods and design of two studies investigating adverse financial events in patients with cancer, the future implications of these findings, and the importance of continued investigation in this area.
12m Jul 20, 2023
12m
S9 Ep11: FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.
14m Jul 17, 2023
14m